A phase 3b trial finds two lower CagriSema doses reduced body weight more than placebo
A phase 3b trial published on 14 November 2026 found that weekly CagriSema at 1.7 mg of each drug, and at 1.0 mg of each, changed mean body weight by -20.7 percent and -21.0 percent at 68 weeks on the efficacy estimand, compared with -2.0 percent on placebo. The trial…